A Fierce Pharma Marketing review of the LinkedIn and Instagram pages of the 20 largest pharmas found that, as of Thursday, ...

Though indexes have rebounded, the first half of the year has been rocky for investors. The market had to digest a variety of ...

Key Takeaways Eli Lilly will acquire Verve for roughly $1 billion Verve is developing a one-time gene-editing treatment for heart disease The company's lead drug, Verve-102, targets a gene linked ...

Eli Lilly and Company (NYSE:LLY) is one of the most frequently discussed stocks on Cramer’s morning show. He is a fan of the firm not only due to its lead in the weight loss market but also due ...

Eli Lilly poised for 30-50% growth in 12 months with a strong value and growth nexus. Click here to read more on LLY stock.

Eli Lilly and Company (LLY)’s share was trading at $765.68 as of 5th June. LLY’s trailing and forward P/E were 62.30 and 35.09 respectively according to Yahoo Finance.

Eli Lilly (NYSE: LLY) has been on fire over the past two years. The drugmaker has generated excellent financial results and ...

US Big Pharma firm Eli Lilly & Co. agreed to buy gene-editing biotech company Verve Therapeutics Inc. for $1.3 billion as the drugmaker focuses its investments in experimental medicine for a ...

June 17 (UPI) -- Eli Lilly and Company said Tuesday it will buy out Boston-based Verve Therapeutics Inc. in a billion dollar deal with plans to advance Verve's new line of experimental cardiac ...

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/ ...